Raynaud’s syndrome is a rare disease which affects blood vessels causing decreased blood flow in the hands and feet. In 1990 Roberto Parmigiani, who suffered from this pathology, went to the baths of Royat in France, where dry carbo-gaseous baths (CO2) were already recognized as an effective treatment for vascular pathologies.
Dr. Parmigiani, driven by his intellectual curiosity and encouraged by the strong evidence about the use of Carbon Dioxide in the thermal field, started to consider that CO2 could also be effective administered intradermally.
Thanks to close contact with Dr. Lattarulo, who in the early 90s was working in the Microangiology Centre of the Monza Polyclinic, Roberto is able to meet Professor Curri, director of the centre, whose invaluable collaboration makes it possible to study the effects of carbon dioxide injection on microcirculation in humans.
The first microangiological evaluations were carried out using a laser doppler flowmetry, which allows to monitor the increase in blood flow and oxygen concentration released in the tissue (Curri, Lattarulo, Albergati).
While in the past carboxytherapy was only intended as an external thermal treatment, the first clinical observations led to a new meaning of carboxytherapy: controlled administration of medical CO2 through intradermal injection.
Carbossiterapia Italiana was founded with the aim to promote clinical research and demonstrate its efficacy.
R&D investments led to a software development, which electronically measures, through sensors, the resistance met by the gas in the tissue.
This improvement, fundament for the therapy efficacy, allowed the doctors to set and monitor the exact gas flow that is actually injected into the tissue. Our CARBOMED device is thus UNI ISO, UNI CEI and IQNET certified.
Carbossiterapia Italiana and Dr. Parmigiani promoted the first clinical studies on carboxytherapy in collaboration with University of Siena and Prof. Carlo D’Aniello
The values are managed by a software that controls a system of solenoid valves allowing to automatically increase or decrease the output flow from the device to balance the variation in resistance. In this way, the doctor can set and monitor exactly the flow of CO2 that is actually injected into the tissue. This electronic flow control system via software is internationally patented, precisely because its precision guarantees control by the doctor and therefore the effectiveness of the treatment, as well as its reproducibility. The device is thus certified UNI ISO, UNI CEI and IQNET.
Our CARBOMED was certified (CE 0051 Class IIB) as the only device within the whole European Community authorized to inject CO2 invasively.
During this years, the first scientific articles were published.
We reunited specialists from Europe, Asia, Latin America and USA to share their personal experiences using our devices in Carboxytherapy.
The first guidelines for its application in plastic surgery, aesthetic medicine, dermatology and phlebology were outlined.
Our continuous efforts in technical innovation led to the development of CDT Evolutionwhich presented updated programs for aesthetic medicine, anti-aging, ulcers, and a portable version too called: CDT Light.
In collaboration with Carboxy Asia “Joy Medicom” (Carbossiterapia Italiana partner since 2002) Shaping Up threads, fabricated in an absorbable and antimicrobial Class IV polydioxanone (PDO), were developed.
Following our costumers’ needs, we launched Élevance, a line of new generation long lasting PDO threads..
We became European exclusive distributor for Raffine microneedling device, which represented our first step toward complementary techniques..
We evolved to CDT Light High Tech, a transportable model with real time input of parameters and a highly improved software.
Our treatment protocols were implemented with new fields of application: trichology, gynecology, andrology and pain therapy.
Nowadays we are focusing on:
Sede Amministrativa: Via Zanella, 48/3
20133 Milano, Italia
Tel: +39 02 730138
P. IVA/Reg. Imp. 09943060153
Developed by
Carbossiterapia Italiana S.r.l.